The Real Cost of 340B Audit Exposure in a Shifting Landscape
Most 340B audit readiness claims have never faced a real audit. As oversight intensifies across federal, state, and manufacturer channels, the cost of being wrong is rising fast.
HRSA reported adverse findings in 66% of its FY2024 audits, and every entity audited had a TPA in place beforehand.
This guide calculates what a single finding actually costs a mid-size DSH hospital, and maps the regulatory pressure now driving that cost higher.
Key Takeaways:
-
HRSA's FY2024 audits show a 66% adverse finding rate, and 68% of entities fail their re-audit.
-
A single adverse finding creates first-year exposure between $3.8 million and $4.9 million for a mid-size DSH hospital.
-
Diversion findings alone can trigger a $3.3 million repayment obligation.
-
Terminated contract pharmacies cost $1.5 million to $4 million in permanent revenue over five years.
-
Oversight is intensifying: a proposed CMS transfer, new state transparency laws, rising manufacturer audits, and pending federal legislation targeting TPAs directly.